Back to results
US 7,452,550 B2Granted
Liposomal antineoplastic drugs and uses thereof
AssigneeHana Biosciences, Inc.
InventorsThomas D. Madden, Sean C. Semple, Quet F. Ahkong
Life of this patent
Estimating the term…
Abstract
This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.
Claims10
A method for modulating the plasma circulation half-life of vinorelbine in a subject, comprising:
- (a) providing a liposomal formulation comprising:
- a liposome having free vinorelbine in solution and precipitated vinorelbine encapsulated therein;
- and
- (b) adding a liposome having no vinorelbine encapsulated therein to the liposomal formulation;
- wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprise sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol %/mol % sphingomyelinl/cholesterol to about 30/50 mol %/mol % sphingomyelinl/cholesterol, wherein the ratio of the vinorelbine to lipid is 0.2-0.3:1 (w/w), and wherein the precipitated vinorelbine in the liposome is at least 50% of the total vinorelbine in the formulation;
- and
- administering the liposomal formulation to the subject, thereby modulating the plasma circulation half-life of vinorelbine in the subject.
4 more elements
A method for modulating the plasma circulation half-life of vinorelbine in a subject, comprising:
- (a) providing a liposomal formulation comprising:
- a liposome having free vinorelbine in solution and precipitated vinorelbine encapsulated therein;
- and
- (b) adding a liposome having no vinorelbine encapsulated therein to the liposomal formulation;
- wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprise sphingomyelin and cholesterol at a ratio of about 55/45 mol %/mol % sphingomyelinl/cholesterol, wherein the ratio of the vinorelbine to lipid is 0.3:1 (w/w), and wherein the precipitated vinorelbine in the liposome is at least 50% of the total vinorelbine in the formulation;
- and
- administering the liposomal formulation to the subject, thereby modulating the plasma circulation half-life of vinorelbine in the subject.
4 more elements
Dependencies are inferred from the claim text.